Fragment-Based Drug Design and Drug Repositioning Using Multiple Ligand Simultaneous Docking (MLSD): Identifying Celecoxib and Template Compounds as Novel Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3)

Journal of Medicinal Chemistry - United States
doi 10.1021/jm101330h
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Chemical Society (ACS)

Related search

Signal Transducer and Activator of Transcription 3 (STAT3)

Science-Business eXchange
2014English

Signal Transducer and Activator of Transcription 3 (STAT3)

Science-Business eXchange
2014English

Signal Transducer and Activator of Transcription 3 (STAT3)

Science-Business eXchange
2013English

STAT3 (Signal Transducer and Activator of Transcription 3)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

Evaluation of Quantitative Assays for the Identification of Direct Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors

Oncotarget
Oncology
2016English

Ligand-Based Drug Design of Novel Aldose Reductase Inhibitors

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2018English

Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer

Annals of the New York Academy of Sciences
GeneticsMolecular BiologyBiochemistryNeuroscienceHistoryPhilosophy of Science
2009English

Signal Transducer and Activator of Transcription 3 (Stat3) Expression and Activation in Rat Uterus During Early Pregnancy

Reproduction
Cell BiologyGynecologyEndocrinologyReproductive MedicineObstetricsEmbryology
2004English

Discovery of Novel KRAS-PDE Inhibitors by Fragment-Based Drug Design

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy